Stone, J. H., Zen, Y. & Deshpande, V. IgG4-related disease. N. Engl. J. Med. 366, 539–551 (2012).
Hamano, H. et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N. Engl. J. Med. 344, 732–738 (2001).
Deshpande, V. et al. Subclassification of autoimmune pancreatitis: a histologic classification with clinical significance. Am. J. Surg. Pathol. 35, 26–35 (2011).
Kamisawa, T. et al. A new clinicopathological entity of IgG4-related autoimmune disease. J. Gastroenterol. 38, 982–984 (2003).
Saeki, T. et al. Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis. Kidney Int. 78, 1016–1023 (2010).
Zen, Y. & Nakanuma, Y. IgG4-related disease: a cross-sectional study of 114 cases. Am. J. Surg. Pathol. 34, 1812–1819 (2010).
Cheuk, W. & Chan, J. K. IgG4-related sclerosing disease: a critical appraisal of an evolving clinicopathologic entity. Adv. Anat. Pathol. 17, 303–332 (2010).
Deshpande, V. et al. Consensus statement on the pathology of IgG4-related disease. Mod. Pathol. 25, 1181–1192 (2012).
Raissian, Y. et al. Diagnosis of IgG4-related tubulointerstitial nephritis. J. Am. Soc. Nephrol. 22, 1343–1352 (2011).
Khosroshahi, A. et al. Brief report: spuriously low serum IgG4 concentrations caused by the prozone phenomenon in patients with IgG4-related disease. Arthritis Rheumatol. 66, 213–217 (2014).
Ryu, J. H., Horie, R., Sekiguchi, H., Peikert, T. & Yi, E. S. Spectrum of disorders associated with elevated serum IgG4 levels encountered in clinical practice. Int. J. Rheumatol. 2012, 232960 (2012).
Carruthers, M. N., Khosroshahi, A., Augustin, T., Deshpande, V. & Stone, J. H. The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann. Rheum. Dis. 74, 14–18 (2015).
Wallace, Z. et al. IgG4-related disease: baseline clinical and laboratory features in 125 patients with biopsy-proven disease. Arthritis Rheumatol. http://dx.doi.org/10.1002/art.39205
Kamisawa, T. et al. Standard steroid treatment for autoimmune pancreatitis. Gut 58, 1504–1507 (2009).
Sah, R. P. & Chari, S. T. Serologic issues in IgG4-related systemic disease and autoimmune pancreatitis. Curr. Opin. Rheumatol. 23, 108–113 (2011).
Nirula, A., Glaser, S. M., Kalled, S. L. & Taylor, F. R. What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr. Opin. Rheumatol. 23, 119–124 (2011).
Aalberse, R. C., Stapel, S. O., Schuurman, J. & Rispens, T. Immunoglobulin G4: an odd antibody. Clin. Exp. Allergy 39, 469–477 (2009).
Mattoo, H. et al. De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. J. Allergy Clin. Immunol. 134, 679–687 (2014).
Zen, Y. et al. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology 45, 1538–1546 (2007).
Okazaki, K. et al. Autoimmune-related pancreatitis is associated with autoantibodies and a Th1/Th2-type cellular immune response. Gastroenterology 118, 573–581 (2000).
Zen, Y. & Nakanuma, Y. Pathogenesis of IgG4-related disease. Curr. Opin. Rheumatol. 23, 114–118 (2011).
Khosroshahi, A., Bloch, D. B., Deshpande, V. & Stone, J. H. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum. 62, 1755–1762 (2010).
Khosroshahi, A. et al. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore) 91, 57–66 (2012).
Vaseemuddin, M., Schwartz, M. M., Dunea, G. & Kraus, M. A. Idiopathic hypocomplementemic immune-complex-mediated tubulointerstitial nephritis. Nat. Clin. Pract. Nephrol. 3, 50–58 (2007).
Baker, R. J. & Pusey, C. D. The changing profile of acute tubulointerstitial nephritis. Nephrol. Dial. Transplant. 19, 8–11 (2004).
Takahashi, N., Kawashima, A., Fletcher, J. G. & Chari, S. T. Renal involvement in patients with autoimmune pancreatitis: CT and MR imaging findings. Radiology 242, 791–801 (2007).
Cornell, L. D. et al. Pseudotumors due to IgG4 immune-complex tubulointerstitial nephritis associated with autoimmune pancreatocentric disease. Am. J. Surg. Pathol. 31, 1586–1597 (2007).
Alkhasawneh, A. & Allan, R. W. IgG4 inflammatory pseudotumor of the kidney. Case Rep. Urol. 2012, 919087 (2012).
Yosh*ta, K. et al. Light-microscopic characteristics of IgG4-related tubulointerstitial nephritis: distinction from non-IgG4-related tubulointerstitial nephritis. Nephrol. Dial. Transplant. 27, 2755–2761 (2012).
Kawano, M. et al. Immunohistochemical characteristics of IgG4-related tubulointerstitial nephritis: detailed analysis of 20 Japanese cases. Int. J. Rheumatol. 2012, 609795 (2012).
Yamaguchi, Y. et al. Characteristic tubulointerstitial nephritis in IgG4-related disease. Hum. Pathol. 43, 536–549 (2012).
Kawano, M. et al. Proposal for diagnostic criteria for IgG4-related kidney disease. Clin. Exp. Nephrol. 15, 615–626 (2011).
Beck, L. H. Jr et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361, 11–21 (2009).
Alexander, M. P. et al. Membranous glomerulonephritis is a manifestation of IgG4-related disease. Kidney Int. 83, 455–462 (2013).
Ong, A. C. & Fine, L. G. Loss of glomerular function and tubulointerstitial fibrosis: cause or effect? Kidney Int. 45, 345–351 (1994).
Debiec, H. & Ronco, P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N. Engl. J. Med. 364, 689–690 (2011).
Jennette, J. C., Iskandar, S. S. & Dalldorf, F. G. Pathologic differentiation between lupus and nonlupus membranous glomerulopathy. Kidney Int. 24, 377–385 (1983).
Davenport, A., Maciver, A. G., Hall, C. L. & MacKenzie, J. C. Do mesangial immune complex deposits affect the renal prognosis in membranous glomerulonephritis? Clin. Nephrol. 41, 271–276 (1994).
CAS PubMed Google Scholar
Vaglio, A., Salvarani, C. & Buzio, C. Retroperitoneal fibrosis. Lancet 367, 241–251 (2006).
van Bommel, E. F., Jansen, I., Hendriksz, T. R. & Aarnoudse, A. L. Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation. Medicine (Baltimore) 88, 193–201 (2009).
Kermani, T. A., Crowson, C. S., Achenbach, S. J. & Luthra, H. S. Idiopathic retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment, and outcomes. Mayo Clin. Proc. 86, 297–303 (2011).
Stone, J. R. Aortitis, periaortitis, and retroperitoneal fibrosis, as manifestations of IgG4-related systemic disease. Curr. Opin. Rheumatol. 23, 88–94 (2011).
Khosroshahi, A. et al. Rethinking Ormond's disease: “idiopathic” retroperitoneal fibrosis in the era of IgG4-related disease. Medicine (Baltimore) 92, 82–91 (2013).
Saeki, T. et al. The clinical course of patients with IgG4-related kidney disease. Kidney Int. 84, 826–833 (2013).
Khosroshahi, A. & Stone, J. H. Treatment approaches to IgG4-related systemic disease. Curr. Opin. Rheumatol. 23, 67–71 (2011).
Ghazale, A. et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 134, 706–715 (2008).
Wallace, Z. S. et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann. Rheum. Dis. 74, 190–195 (2015).
González, E. et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int. 73, 940–946 (2008).
Mizushima, I. et al. Clinical and histological changes associated with corticosteroid therapy in IgG4-related tubulointerstitial nephritis. Mod. Rheumatol. 22, 859–870 (2012).
Austin, H. A. 3rd, Illei, G. G., Braun, M. J. & Balow, J. E. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J. Am. Soc. Nephrol. 20, 901–911 (2009).
Sarafidis, P. A., Khosla, N. & Bakris, G. L. Antihypertensive therapy in the presence of proteinuria. Am. J. Kidney Dis. 49, 12–26 (2007).
Wheeler, D. C. & Bernard, D. B. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am. J. Kidney Dis. 23, 331–346 (1994).
